DI-UMONS : Dépôt institutionnel de l’université de Mons

Recherche transversale
(titres de publication, de périodique et noms de colloque inclus)
2007-01-01 - Article/Dans un journal avec peer-review - Anglais - 9 page(s)

Saussez Sven , Decaestecker Christine, Lorfevre François, Cucu Diana-Raluca, Mortuaire Geoffrey, Chevalier Dominique, Wacrenier Agnès, Kaltner Herbert, André Sabine, Toubeau Gérard, Camby Isabelle, Gabius Hans-Joachim, Kiss Robert, "High Level of Galectin-1 Expression Is a Negative Prognostic Predictor of Recurrence in Laryngeal Squamous Cell Carcinomas" in International Journal of Oncology, 30, 5

  • Edition : DA Spandidos, Athens (Greece)
  • Codes CREF : Histologie (DI3212), Cancérologie (DI3349)
  • Unités de recherche UMONS : Anatomie et Biologie cellulaire (M112), Histologie (M118)
Texte intégral :

Abstract(s) :

(Anglais) Monitoring of gene-expression profiles is assumed to refine tumor characterization of laryngeal squamous cell carcinomas (LSCCs) with a therapeutic perspective. This is especially expected for adhesion/growth-regulatory effectors such as galectins, a class of endogenous lectins. Using computer-assisted microscopy, we investigated the prognostic value contributed by the quantitative determination of the immunohistochemical levels of expression of galectin-1, -3 and -7 in a series of 62 LSCCs including 42 low- and 20 high-stage LSCCs. As galectin-1 may have a key role leading to a tumor escape from immune surveillance, we also investigated whether or not the level of galectin-1 expression correlated with lymphocyte infiltration in LSCCs. The immunohistochemical determination of expression of galectin-1 is of prognostic value in human squamous laryngeal cancers. LSCCs that display high levels of galectin-1 have worse prognoses than laryngeal cancers with low levels of galectin-1 expression. Elevation of galectin-1 levels in laryngeal cancers can contribute to the process of tumor immune escape by killing the activated T-cells and other protumoral activities such as promoting motility or activity of oncogenic H-Ras proteins. The quantitative determination of galectin-1 in LSCCs is an independent prognostic marker when opposed to TNM staging. It has the potential to identify patients unlikely to benefit from T-cell-mediated immunotherapy, although the definitive effector function from its pro- and antitumoral activity profile has not been delineated.

Identifiants :
  • ISSN : 1019-6439